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Abstract: Glioblastoma (GBM) is an extremely aggressive tumor of the central nervous system, with
a prognosis of 12–15 months and just 3–5% of survival over 5 years. This is mainly because most
patients suffer recurrence after treatment that currently consists in maximal resection followed by
radio- and chemotherapy with temozolomide. The recurrent tumor shows a more aggressive behavior
due to a phenotypic shift toward the mesenchymal subtype. Proneural-mesenchymal transition
(PMT) may represent for GBM the equivalent of epithelial–mesenchymal transition associated with
other aggressive cancers. In this review we frame this process in the high degree of phenotypic inter-
and intra-tumor heterogeneity of GBM, which exists in different subtypes, each one characterized by
further phenotypic variability in its stem-cell compartment. Under the selective pressure of different
treatment agents PMT is induced. The mechanisms involved, as well as the significance of such
event in the acquisition of a multitherapy resistance phenotype, are taken in consideration for future
perspectives in new anti-GBM therapeutic options.
Keywords: epithelial–mesenchymal transition (EMT); glioma; tumor heterogeneity; phenotypic
plasticity; chemoresistance; proneural-mesenchymal transition (PMT); glioblastoma
1. Introduction
Glioblastoma (GBM) is the most common intrinsic and aggressive primary brain tumor in adults.
It is characterized by alteration in crucial signaling pathways that results in the acquisition of hallmarks
properties of cancer. Consequently, GBM exhibits a diffused infiltration throughout the brain rendering
it incurable by surgery [1]. Since the 1970s, the first-line adjuvant treatment after surgery is represented
by radiotherapy that has been recently been combined with targeted chemotherapy approaches
involving DNA alkylating agents, such as temozolomide (TMZ). Unfortunately, this therapeutic
option shows many limitations in its efficacy and almost all patients present the progression of the
disease after a mean progression-free survival of 7–10 months [2,3]. Therefore, despite therapeutic
strategies and supportive care having been improved, GBM remains characterized by a very poor
quality of life and prognosis, with a mean median survival time of 15 months [2]. The poor outcome
of GBM has been ascribed to the high degree of intra-tumor heterogeneity that occurs at multiple
levels, including histopathological, transcriptional and genomic [4–7]. In the effort to facilitate the
development of more effective target therapies, large-scale genomic projects on patient specimens
have adopted to identify GBM molecular subtypes associated with prognostic values [8,9]. Ultimately,
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GBM has been classified into at least four molecular subgroups namely proneural (PN), neural (NL),
classical (CL) and mesenchymal (MES) [9]. Since typical molecular alterations, sensitivity to therapy
and prognosis are associated with each subgroup, this classification has implications in selecting
target therapy strategies. The MES subtype is the most aggressive and strongly associated with
a poor prognosis compared to PN subtype, in addition, a shift from PN to MES subtype can occur
in patients following radiation therapy and chemotherapy [10]. The molecular events driving this
transition are similar to those driving the epithelial-mesenchymal transition (EMT) in carcinomas cells.
EMT has been described as a crucial mechanism by which carcinoma cells enhance their invasive
capacity by losing cell polarity and intercellular adhesions acquiring a mesenchymal and more motile
phenotype, thus promoting cancer metastasis [11]. The molecular mechanisms driving EMT have
been investigated and highlight the down-regulation of E-cadherin together with other epithelial
specification genes paralleled by the up-regulation of mesenchymal markers such as N-cadherin,
vimentin and fibronectin [11,12]. Expression of mesenchymal markers by primary tumors correlates
with enhanced invasiveness and poorer clinical prognosis. Moreover, mounting evidence associates
EMT to chemotherapy resistance [13–16]. In general, cancer cell lines with epithelial features are more
sensitive to chemotherapy drugs compared to those displaying a mesenchymal phenotype; on the
contrary, the acquisition of resistance to several drugs is accompanied by the expression of mesenchymal
markers [17,18]. Many signals that unleash EMT are involved in triggering and maintaining the
mesenchymal state and converge in the activation of a network of master transcriptional regulators
(EMT-TF) that drive the EMT process. Among these, a major role is played by ZEB 1/2, Snail 1/2/3, and
Twist 1/2 [12,19]. The same EMT-TF network is also active in PMT and there is evidence, both in vitro
and in vivo, supporting a critical role for these factors in the acquisition of the MES phenotype [20–22].
As for EMT, PMT has been shown to have a role in conferring an unfavorable prognosis. Specifically,
radiation and chemotherapy induced resistance by promoting a PN to MES phenotypic shift, therefore
investigation of PMT mechanisms is critical for improving therapy selection and patient outcomes.
2. Phenotypic Heterogeneity and Plasticity in Glioblastoma
GBM exhibits a high degree of phenotypic heterogeneity that molecularly corresponds to different
gene expression signatures. Based on expression profiling studies, GBM has been subdivided
into different molecular subtypes that have a prognostic value and delineate a pattern of disease
progression [8,9,23]. One of the first pioneering studies in this sense is the work by Phillips et al.,
who defined three subclasses among high-grade gliomas, including PN, MES, and proliferative
(Prolif) subtypes. The PN group expresses genes associated with the process of neurogenesis and
is characterized by a better prognosis, while the MES and Prolif subtypes express genes of either
cell proliferation or angiogenesis, respectively, and are both characterized by poor prognosis [8].
Subsequently, the deep molecular analysis by The Cancer Genome Atlas (TCGA) project has divided
GBMs into four subclasses, including CL and NL, other than PN and MES [9]. Among all malignant
gliomas, the most prevalent subtypes are PN (32.73%) and MES (32.4%), followed by CL (19.77%)
and NL (15.09%) (Figure 1) [24]. Indeed, PN was largely observed in grade II and III gliomas, with a
prevalence in oligodendrogliomas, while CL and MES were mostly observed in GBM [24,25]. According
to recent comprehensive survival analyses, PN displays a good prognosis, NL has an intermediate
correlation with overall survival, while MES and CL have the worst clinical outcomes [24,25].
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progression from low- to high-grade gliomas is unlikely because secondary GBMs are characterized 
by a PN signature 26. Conversely, the molecular signatures that define GBM subtypes are not a 
fixed feature of each tumor case, but may change after treatment and/or disease progression. Phillips 
et al. demonstrated that, upon recurrence, tumors tend to shift toward the mesenchymal phenotype 
reminiscent of EMT that is associated with increased malignant behavior of epithelial tumors. 
Particularly, they observed a loss of PN gene expression profile and a gain of the MES one, including 
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hallmark of glioma aggressiveness and is strongly associated to poor prognosis. The ability of 
tumors to change subclass suggests that the tumor subtypes represent alternate differentiation states 
of the disease, but the unidirectionality of the shift PN-MES upon recurrence led us to hypothesize 
the acquisition of new genetic and epigenetic abnormalities toward the MES subtype. Accordingly, it 
has been recently shown that the PN gene ASCL1 represses mesenchymal features by directly 
downregulating the expression of N-Myc downstream regulated gene 1, NDRG1. Abrogation of 
ASCL1 or overexpression of NDRG1 in PN glioma stem cells (GSCs) results in PMT, while 
overexpression of ASCL1 in MES GSCs enhances their malignant features 27. Different studies 
outlined that there is still a degree of heterogeneity within each molecular subclass. For example, 
within the PN group, we have previously shown that the expression of the transcriptional regulator 
PATZ1 is able to stratify patients in two subgroups with different overall and progression-free 
survival, in which higher levels of PATZ1 correlate with a longer survival 28. Interestingly, the PN 
subgroup with lower levels of PATZ1 showed increased levels of the G-protein coupled receptor 
CXCR4, a well-known inducer of the mesenchymal phenotype in GBM 29,30, which has been 
shown to be downregulated by PATZ1 overexpression in GBM cells 28. The trans-differentiation of 
GBM cells from PN to MES may imply a reprogramming process that leads differentiated cells to 
reacquire the capacity to differentiate into different cell types, i.e., to acquire stem-like features, for 
which OLIG2 has been shown to play a crucial role 31. Indeed, there is a theory, developed by a 
computational methodology, that most GBM subtypes arise as, and evolve from, a PN progenitor 
32. The classification by TCGA highlights the association between treatment resistance and the 
stem cell phenotype, being the PN group (characterized by a stem-like signature) the only one fully 
unresponsive to aggressive chemo- and radio-treatment 9. However, patients with a MES signature 
belong to the poorest prognosis subclass and are resistant to standard treatments 33, and PN 
Synaptotagmin expression
EGFR overexpression
Intermediate correlation with OS
PN
33%
MES
32%
CL
20%
NL
15%
OLIG2 overexpression
PDGFRA amplification
IDH1 mutation
Good prognosis
Loss of chromosome 10 
EGFR amplification
Worst clinical outcome
YKL404 overexpression
Loss of NF1
Worse prognosis than Neural
Figure 1. Glioblastoma subtype classification and prevalence of each subclass in all malignant gliomas.
Some of the specific molecular and clinical characteristics are indicated on the side. OS, Overall Survival;
NL, neural; PN, proneural; MES, mesenchymal; CL, classical.
Even though each subclass is associated with different mutations, such as platelet derived growth
factor receptor A (PDGFRA) amplification in PN and loss of NF1 in MES, it is still not clear if these
different subtypes are essentially different tumors or if they can evolve from each other. However,
different subtypes can co-exist in the same tumor [6,7], and shifts in subtypes can occur. To our
knowledge, there is no evidence of such shifts in low-grade gliomas that could justify a progression to
high-grade gliomas (secondary GBMs). Indeed, a PMT associated to glioma progression from low-
to high-grade gliomas is unlikely because secondary GBMs are characterized by a PN signature [26].
Conversely, the molecular signatures that define GBM subtypes are not a fixed feature of each tumor
case, but may change after treatment and/or disease progression. Phillips et al. demonstrated that,
upon recurrence, tumors tend to shift toward the mesenchymal phenotype reminiscent of EMT that is
associated with increased malignant behavior of epithelial tumors. Particularly, they observed a loss of
PN gene expression profile and a gain of the MES one, including frequent loss of OLIG2 expression
and upregulation of YKL40 [8]. Indeed, MES phenotype is the hallmark of glioma aggressiveness
and is strongly associated to poor prognosis. The ability of tumors to change subclass suggests that
the tumor subtypes represent alternate differentiation states of the disease, but the unidirectionality
of the shift PN-MES upon recurrence led us to hypothesize the acquisition of new genetic and
epigenetic abnormalities toward the MES subtype. Accordingly, it has been recently shown that the
PN gene ASCL1 represses mesenchymal features by directly downregulating the expression of N-Myc
downstream regulated gene 1, NDRG1. Abrogation of ASCL1 or overexpression of NDRG1 in PN
glioma stem cells (GSCs) results in PMT, while overexpression of ASCL1 in MES GSCs enhances their
malignant features [27]. Different studies outlined that there is still a degree of heterogeneity within
each molecular subclass. For example, within the PN group, we have previously shown that the
expression of the transcriptional regulator PATZ1 is able to stratify patients in two subgroups with
different overall and progression-free survival, in which higher levels of PATZ1 correlate with a longer
survival [28]. Interestingly, the PN subgroup with lower levels of PATZ1 showed increased levels
of the G-protein coupled receptor CXCR4, a well-known inducer of the mesenchymal phenotype in
GBM [29,30], which has been shown to be downregulated by PATZ1 overexpression in GBM cells [28].
The trans-differentiation of GBM cells from PN to MES may imply a reprogramming process that leads
differentiated cells to reacquire the capacity to differentiate into different cell types, i.e., to acquire
stem-like features, for which OLIG2 has been shown to play a crucial role [31]. Indeed, there is a theory,
developed by a computational methodology, that most GBM subtypes arise as, and evolve from, a PN
progenitor [32]. The classification by TCGA highlights the association between treatment resistance
and the stem cell phenotype, being the PN group (characterized by a stem-like signature) the only
one fully unresponsive to aggressive chemo- and radio-treatment [9]. However, patients with a MES
signature belong to the poorest prognosis subclass and are resistant to standard treatments [33], and
PN tumors tend to shift toward the MES phenotype upon recurrence, or in response to radiation
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therapy, thus manifesting phenotypic plasticity [8]. Therefore, the tumor plasticity may render GBM
cells more invasive or resistant to current therapies at different stages in their development [31].
Another theory, that has been applied as an explanation of the cancer plasticity in GBM, is the
clonal variation, based on the clonal evolution model of cancer, which attributes the origin of clonal
expansions to the accumulation of mutations and/or epigenetic changes. This is not contradictory with
the stem cell theory, because genetic or epigenetic variations within the stem-like cells could be the
culprits of the outgrowth of pre-existing resistant subpopulations upon treatment. Indeed, a single
GBM can give rise to a variety of stem-like clones with different degrees of drug- and radio-resistance.
The variation in multitherapy resistance is due to continual shifts along the PN-MES axis, associated
with altered DNA methylation of MES transition regulators [10].
Finally, tumor microenvironment (TME) may also be a source of heterogeneity in cancer. A recent
study proposed macrophages/microglia as an essential component that can regulate PN-MES transition
in GSCs [34]. Consistently, the MES subtype of GBM exhibits a high degree of necrosis [35] and
macrophage/microglia infiltration [36,37]. Bhat et al. demonstrated that the intratumoral PN-MES shift
consequent to radiotherapy was linked to NF-κB activation and macrophages/microglia involvement in
GBM [34]. More recently, the same group reported that this pro-inflammatory response transcriptionally
regulates CD109 via C/EBPβ [38].
An integration of all these sources of heterogeneity could probably be the true explanation of
tumor plasticity in GBM as in all types of cancer. GBM subtypes should not be considered stable
phenotypes but dynamic states, which shift from one to another one upon treatment-dependent
conditions in the microenvironment.
3. Signaling Mechanisms in PMT
The two GBM subtypes that appear consistently in the different molecular classification attempts
are the PN and the MES groups, the latter being associated with a worst prognosis. In the following
paragraph we will highlight some of the main signaling pathways and factors that are hijacked by
GBM to acquire the MES phenotype (Figure 2).
3.1. STAT3 and C/EBPβ: Two Master Regulators
The research group of Iavarone [39], in a pioneer attempt to identify master regulators (MRs) of
the mesenchymal gene expression signature (MGES), ends up with a list of six MRs (STAT3, bHLH–B2,
C/EBP, FOSL2, ZNF238, and RUNX1), with STAT3 and C/EBPβ at the top of the hierarchical regulatory
network. Specifically, they demonstrated that C/EBPβ and STAT3 were (i) responsible for MGES
expression, (ii) able to reprogram neuronal stem cells towards a MES phenotype, and (iii) responsible
for the aggressiveness traits of glioma cells. One of the most interesting hypotheses that emerged from
their work is that the transforming ability of these two TFs could come from their opposing “normal”
roles. The fact that STAT3 is an inducer of astrocyte differentiation while C/EBPβ push towards
neurogenesis could constitute a conflicting situation that finally evolves driving neural stem/progenitor
cells towards a MES phenotype.
STAT3 was demonstrated to be a key player in the acquisition of radiation-induced PMT. Indeed,
it was demonstrated that after radiation regimens STAT3 turned out to be activated and notwithstanding
its activation was temporary, it was sufficient to sustain a durable PMT [40]. The most interesting
point was that by inhibiting JAK2, a STAT3 activator, by AZD1480 or ruxolitinib in combination with
radiation, it was possible to prevent PMT and obtain a reduction in cell aggressiveness. Importantly,
experiments performed with FVB/N mice allografted with PDGFRα+ proneural high-grade glioma
cells showed that mice treated with AZD1480 in combination with radiation had a stronger benefit in
terms of survival with respect to those subjected to radiation treatment alone, thus further sustaining
a central role for STAT3 in PMT–dependent cell aggressiveness [40].
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3.2. TAZ
In an attempt to further increase the number of MRs of the MES phenotype, the group of Aldape [41]
found out other potential factors positively correlated with the MES signature, i.e., MAFB, HCLS1, and
the two downstream factors of the Hippo pathway YAP and TAZ, that have been already demonstrated
to play a role in the EMT in other cancer types. Authors showed that TAZ was not interdependent
on STAT3 and C/EBPβ and vice versa, thus representing an alternative route contributing to the MES
phenotype in GBM. They found that the TAZ promoter is hypermethylated in low-grade gliomas (grade
II and III) with respect to grade IV ones (i.e., GBM), in which it is not methylated and, as a consequence,
TAZ is expressed. They provided compelling evidences for a role of TAZ in driving the MES phenotype
exploiting the RCAS/N–tva mouse model. Using this model, they overexpressed PDGF–B (a proneural
tumor driver), TAZ, or PDGF–B plus TAZ in neural progenitor cells observing that mice overexpressing
PDGF-B developed tumors with PN characteristics (predominantly grade II), those overexpressing
TAZ were not able to drive tumor formation, but the combination of the two lead to the formation
of grade III and IV tumors with a high expression of MES markers (FN1, CD44, and CTGF), thus
providing an in vivo proof that TAZ is able to contribute to drive tumors towards a MES phenotype.
Very recently, CD109 was identified as an upstream regulator of the YAP/TAZ pathway involved in the
ionizing radiation (IR)-dependent PMT at the invading edge of GBM [38].
3.3. The Extracellular Environment and the NF-κB Pathway
A point that is still under debate is whether the PMT is an intrinsic process, or whether it is
induced by factors that are present in the extracellular TME, or whether it is due to a combination of
both. In support of a prominent role coming from the TME is the work by the laboratories of Sulman
and Aldape [34]. In this study they showed that glioma sphere cultures from MES GBMs negative for
the glioma CpG island methylator phenotype (MES/CIMP–GBMs) show an overall PN signature and
that this was due to the in vitro lack of signaling from the TME. In an attempt to decipher the signaling
pathways involved in this phenomenon they built up a TNF-α→ NF–κB axis that controlled the MRs
STAT3, C/EBPβ, and TAZ. They provided evidence that macrophages/microglia could be involved in
inducing MES differentiation. This was further supported by immunohistochemical analyses of GBMs
on serial paraffin–embedded sections in which it was shown that single GBMs displayed both PN and
MES regions, and that the MES regions were positive for NF-κB activation and were in close contact
with macrophages/microglia infiltration zones. However, the same authors discussed some cases
where the phenotype of MES GSCs did not change upon removal from their TME, thus suggesting
that also intrinsic mechanisms could be responsible for such an aggressive phenotype. It was later
shown that the serine/threonine kinase MLK4 could be an important factor in the TNF-α→ NF-κB
axis [42]. MLK4 has been found highly expressed in MES GSCs and its expression was required to
sustain the MES phenotype and to allow the growth of MES GSCs both in vitro and in vivo. Indeed,
MLK4 binds and phosphorylates IKKα, which is involved in releasing NF-κB from its cytoplasmic
inhibitor IκB, thus leading to NF-κB activation. In an immunohistochemical screening performed onto
87 high-grade gliomas specimens, the expression of MLK4 strongly correlated with that of CD44 (MES
GBM marker) and turned out to be almost mutually exclusive with that of OLIG2 (PN GBM marker).
More importantly, high MLK4 expressing patients displayed a shorter survival, thus indicating MLK4
as a predictor of worst prognosis in CD44-positive (MES GBMs) cases.
A very interesting work describing the relationship between extracellular stimuli and the PN/ MES
phenotype, still converging onto the NF-κB and STAT3 pathways, is the one by the Cheng group [43].
In this study, the role of miR-125b and miR-20b in the modulation of the MES and PN phenotypes
was highlighted. The authors demonstrated that the Wnt pathway induce the expression of these
two miRNAs and that the Wnt pathway inhibitor FZD6 is one of their targets. FDZ6 is involved in
the activation of an inhibitory pathway towards one of the final executors of the Wnt pathway, i.e.,
TCF4, thus blunting an autoregulatory activating loop between the Wnt pathway and miR-125b and
miR-20b (Wnt→ TCF4→ (miR-125b and miR-20b) —| FDZ6 —| TCF4). The most interesting point
Int. J. Mol. Sci. 2019, 20, 2746 6 of 14
was that FDZ6, beside inhibiting TCF4 expression, was involved in the activation of a pathway (FZD6
→ CAMKII→ TAK1) leading to the activation of both STAT3 and NF-κB, factors that, as described
above, play a key role in driving the MES phenotype. From one side, the Wnt pathway is responsible
for the cell growth and self-renewal properties of PN GBM, on the other side, when blunted by FZD6,
it allows the activation of a signaling boost towards a more aggressive phenotype.
Always related to the NF-κB pathway is the work by the Park group [44]. In this study they
demonstrated that the perinecrotic regions of GBM display an upregulation of transglutaminase
2 (TGM2) expression, providing evidence that TGM2 is involved in the transition towards a MES
phenotype; indeed, they demonstrated that, upon TGM2 silencing in MES GSCs, both MES MRs and
MES markers were downregulated, while the contrary occurred in PN GSCs by TGM2 overexpression.
These results were also confirmed in vivo using orthotopic mouse models. They showed that TGM2
is able to induce the degradation of GADD153, an inhibitor of C/EBPβ transcriptional activity.
Furthermore, C/EBPβ expression was increased upon TGM2 overexpression and they provided
evidences that the silencing of GADD153 was responsible for a strong induction of C/EBPβ. Authors
demonstrated that radiation treatment induced TGM2 expression and TNF-α secretion was responsible
for the activation of a signaling pathway leading to the activation of NF-κB through the downregulation
of the NF-κB negative regulator IκBα. Importantly, they demonstrated that these findings were linked
with a therapeutic opportunity: By generating an orthotopic xenograft mouse model implanted with
MES GSCs, they demonstrated that treatment with the TGM2 inhibitor GK921 is able to improve
survival and decrease the tumor size in mice. Furthermore, they showed that TGM2 inhibition
overcomes the transition of cancer cells towards a MES phenotype that occurs upon radiotherapy, thus
increasing the efficacy of the irradiation.
3.4. Multiple Routes to Drive the MES Phenotype
The Bogler group [45] found that STAT3 could be activated by the cooperation between
two transmembrane receptors that are frequently overexpressed in GBM: The hepatocyte growth
factor receptor (c–Met) and a constitutive active mutant of the epidermal growth factor receptor
(∆EGFR/EGFRvIII). This signaling pathway relies on the hepatocyte growth factor (HGF) and forms
a self–sustaining loop, i.e., HGF→ c–Met/∆EGFR/EGFRvIII→ STAT3/others→ HGF, thus providing
evidence to the presence of an autonomous autocrine loop.
FOXM1, a member of the Fox family of transcription factors, is involved in MES transition being
responsible for the acquisition of mesenchymal features in glioma cells [46]. It was demonstrated
that its action is due to the activation of the EGFR/AKT/GSK3β signaling pathway mediated by
the FOXM1–dependent transcriptional activation of ADAM17. Interestingly, the EGFR/AKT/GSK3β
pathway acts by stabilizing FOXM1 protein levels, thus constituting a self–sustaining loop [46]. It is
relevant to underline that EGFR is well–known to be able to activate both the PI3K/AKT and Ras/MAPK
pathways that exert a central role in driving tumor progression.
ALDH1A3 is highly expressed in MES GSCs, and ALDH1 inhibition by diethylaminobenzaldehyde
attenuates the radiation-induced PMT of GSC [47]. Moreover, ALDH1A3 was shown to be a key player
in driving the MES phenotype in GBM [48] and that the transcription factor FOXD1 regulates the
transcription of the ALDH1A3 gene [49].
The hedgehog (HH) pathway has been widely involved in GBM [50], and in particular in
controlling, in cooperation with the PI3K/Akt/mTOR pathway, several aggressive features of the
GBM-initiating cells (GICs) [51]. In mouse cells, transcription of FOXD1 (also known as BF-2) was
found to be induced by SHH (sonic hedgehog) stimulation and by Gli1 overexpression, a downstream
effector of the SHH receptor [52], and Gli1 is known to be involved in GBM [50]. To our knowledge there
are no data regarding the transcriptional regulation of FOXD1 by Gli1 in GBM, but it is conceivable that
it could be under the control of SHH in this tumor as well. In addition, it was also demonstrated that
factors able to stabilize the ALDH1A3 protein have a role in sustaining the MES phenotype. Indeed,
this was the case of USP9X, a deubiquitinase, involved in the deubiquitination of ALDHA3, whose
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expression was responsible for self-renewal, tumorigenicity, and radio/chemoresistance of MES GSCs,
and that was demonstrated to represent a promising pharmacological target for tumors expressing
high levels of ALDH1A3 [53].
Although we are aware of not having provided a comprehensive review of all the mechanisms
involved in the PMT, it appears evident that the MES phenotype relies on the activation of few MRs,
but the pathways leading to their activation are multiples and other pathways can contribute to this
process. A point which, at the moment, has not been clarified yet is whether GBM cells selectively hijack
all these mechanisms or whether they somehow concur to drive the acquisition of a MES phenotype.
Even though not yet replicated in humans, the various attempts to interfere singularly with each of
these mechanisms led to promising results in terms of possibility to enhance the survival expectations
of patients. However, the most interesting results could come by trying to adopt combinatorial
therapeutic approaches.
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Figure 2. Signaling pathways in the proneural-mesenchymal transition (PMT). PMT is driven by the
activation of a restrict set of master regulators (MRs), among which a key role is exploited by STAT3,
C/EBPβ, and TAZ. NF-κB is an upstream regulator of these MRs, and several factors, both intrinsic and
from the extracellular environment, can lead to its activation. Beside MRs, the activation of a plethora
of factors by several distinct pathways play also a relevant role in driving the PMT.
4. PMT in Multitherapy Resistance
Current treatments for GBM, consisting of radiotherapy and concomitant adjuvant chemotherapy
with TMZ, are still ineffective, since the tumor inevitably elapses and the prognosis is extremely poor,
being fatal in 90% of patients 5 years after initial diagnosis [2,54]. A sub-po ulation of tum r cell
with ste -like r perti s, the GSCs or GICs, which are responsible for tumor initiatio , is specifically
endowed to resist or adapt to the standard thera ies, leading to therapy resistance [54]. It has been
recently proposed that GSCs can be sub-divided into two main groups, characterized by ith r a PN or
a MES ph no ype [5 ]. Segerman et al. have sh wn that a single GBM gives rise to ma y GIC clones
with different resistance to therapies. However, they observed that, upon treatment with radiother py
and different drugs, all clones become resistant to th same treatm nts acquir ng a multitherap
resistance phenotype with differen degrees of resista ce along a continuous distribution, suggestive of
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a dynamic process in the GIC population [10]. The gene set enrichment analysis (GSEA) of these clones
showed a clear connection of multitherapy resistance to MES signature on one side, and sensitivity
to PN signature on the other side. Therefore, it is likely that a primary GBM contains both PN and
MES GSCs, but the treatment pushes PMT in GSCs, resulting in a prevalence of MES GSCs in the
recurrent tumor (Figure 3). The passage from PN to MES upon radio- and chemotherapy is governed
by epigenetic changes, specifically DNA methylation, on regulatory elements of master regulators of
the MES GBM subtype, such as FOSL2 [10,39]. It is likely that the inflammatory microenvironment
consequent to the exposure to the therapeutic agents could be responsible for such dynamicity. More
recently, Minata et al. reported that, upon exposure to IR, CD109 is highly induced, while CD133 is
downregulated, in PN GSCs present at the invading edge of the tumor, which is often unresectable
upon surgery. The resulting switch from PN to MES phenotype could explain the IR-dependent
tumor recurrence. Mechanistically, IR activates NF-κB via ATM, which in turn induces CD109 via
C/EBPβ. They also showed that CD109 acts upstream of the YAP/TAZ signaling pathway, which
could contribute to the PMT of the CD109+ tumor cells [38]. However, due to the reversible nature
of the process, elucidating the mechanisms of PMT may help to identify new strategies to sensitize
GBM to treatment. Consistently, it has been shown that blockage of STAT3 activation is able to inhibit
radiation-induced PMT, resulting in prolonged survival of mice with PN GBM [40]. Also, silencing of
LncRNA-H19 was shown to decrease chemoresistance of human glioma cells to TMZ by suppressing
PMT via the Wnt/β-catenin pathway [56].
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Figure 3. PMT upon radio- and chemotherapeutic treatment of GBM. A single GBM contains GSCs of
both PN and MES phenotype. Upon treatment, most of them pass from the PN to the MES phenotype
as a result of different treatment-dependent events, some of which are shown below. In purple: cells
with proneural features; in grey: cells with mesenchymal features.
Another therapy experimented for GBM is the antiangiogenic therapy (e.g., bevacizumab/
anti-VEGF) that, by reducing vascular permeability is thought to reduce the tumor burn of a highly
vascularized cancer such as GBM. However, after an initial delay in tumor progression, chronic exposure
to antiangiogenic therapy ultimately provoked an aggressive treatment-resistant phenotype [57]. Also,
in this case, gene expression and GSEA of resistant clones showed an increase in genes associated with
the MES GBM subtype, thus identifying a PMT in tumors resistant to antiangiogenic therapy [58].
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Upregulation of MES markers with concomitant downregulation of the PN phenotype, consequent
to increased intracellular levels of reactive oxygen species (ROS), was also observed in primary GSCs
treated with the cannabinoid and redox modulator cannabidiol (CBD), thus suggesting a combinatorial
approach consisting of CBD and small molecule inhibitors of ROS for a more successful treatment of
GBM [54].
5. Conclusions and Therapeutic Perspectives
It seems clear that in order to combat GBM, there must be a shift from classical cytotoxic
chemotherapy to more targeted therapies, taking into account the high degree of heterogeneity and
molecular complexity of the tumor. Subtyping GBM is a key process in order to impact a patient’s
survival providing them targeted therapies. Gene molecular signatures are features associated with
specific tumor phenotype. The definition of pathways and key molecules involved in tumor signaling,
especially those involved in GSC resistance and invasion, will provide therapeutic opportunities that
could be translated into GBM treatment clinics (Figure 4).
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Despite a continuous effort to design new targeted drugs, such as molecular pathway inhibitors,
these molecules often result in toxicity and acquired resistance. The high level of cross-stimulation
among the targets of the new therapeutic agents poses a major obstacle to their successful development.
Blocking one target often allows others to act as salvage mechanisms for cancer cells. The case of the
constitutively active EGFRvIII mutant is a paradigmatic example. EGFRvIII expression influences
multiple aspects of GBM biology, including the rising of glioma ste -like cells and maintenance of tumor
heterogeneity [59], thus encouraging the development of therapeutics to block its activity. Nevertheless,
GBM may escape from EGFR-targeted therapies by the occurrence of alternative kinase signaling
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pathways, as those dependent from PDGFRβ and MET, which compensate the pharmacological
perturbations [60,61]. Therefore, testing combinations of diverse targeted drugs and identifying key
biomarkers to improve selection of patients most likely to benefit, is an essential issue in the novel
treatment modalities against GBM.
Notably, in addition to GBM heterogeneity, including tumor cell plasticity as the source of
cancer stem cells, the existence of the blood-brain barrier (BBB) represents an important limitation
to effective therapy. GBMs are indeed “protected” by their localization beyond the BBB, which
limits the penetration of many antineoplastic drugs [62]. A variety of approaches are currently
under investigation for overcoming the drug delivery issues including invasive techniques, e.g., BBB
transient disruption, intracerebroventricular and intrathecal infusion, and non-invasive techniques, e.g.,
inhibition of multidrug eﬄux transporters and various pharmacological strategies for modifying drugs
to facilitate their transport across the BBB. Among the last ones, targeted drug delivery nanovectors
are receiving increasing attention for their ability to transport drugs within the cerebral tissue with
minimal off-target toxicity. Drug-loaded nanosystems conjugated to targeting agents as peptides,
antibodies, or oligonucleotide aptamers are now at the forefront of innovation [63,64].
In conclusion, it is important to understand the impact of a treatment on the biologic response
and selective pressure within the tumor and its subsequent behavior, in order to make changes in the
treatment regimen that could target a tumor that has evolved into a different and more aggressive form.
In particular, since it is clear that resistance is associated with a MES-like cell state of the GICs, specific
inhibitors of the MES phenotype in combination with the standard therapeutics could synergistically
inhibit GBM progression and should be considered for the development of novel therapeutics.
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